普通人群与高危人群中胰腺癌临床预测模型:一项系统综述
本系统综述检索MEDLINE、Embase和Web of Science至2021年11月,纳入33项研究、描述38个胰腺癌风险预测模型,涵盖普通人群、糖尿病患者及有胃肠道等症状者;常用预测因子为吸烟、年龄、糖尿病史、慢性胰腺炎和体重指数,评估模型性能的25项研究中C统计量为0.61至0.98,仅6项研究被评为低偏倚风险;作者认为低偏倚风险模型仍需外部验证和实施研究。
要点
- 共纳入33项研究、38个胰腺癌风险预测模型,仅6项被评为低偏倚风险。
- 评估模型性能的25项研究中,C统计量范围为0.61至0.98。
- 低偏倚风险模型仍需外部验证和实施研究以支持临床决策。
核心结论
- 已针对不同目标人群开发了许多胰腺癌临床风险预测模型,虽已识别出低偏倚风险研究,但这些研究仍需外部验证和实施研究以确保其有益于临床决策。
研究设计与样本
- 系统综述,检索MEDLINE、Embase和Web of Science自各数据库建库至2021年11月的相关文章,由2名独立评审员进行研究选择和数据提取,并应用预测模型偏倚风险评估工具(PROBAST)评估偏倚风险。
- 共纳入33项研究,描述38个风险预测模型;排除人群重叠的研究后,共包括15,848,100名参与者,其中58,313例被诊断为胰腺癌。
- 8项研究对模型进行了外部验证,13项进行了内部验证;模型针对普通人群(n=14)、糖尿病患者(n=8)以及有胃肠道(及其他)症状者(症状包括腹痛、不明原因体重减轻、黄疸、排便习惯改变和消化不良;n=11)。
主要发现
- 模型中常用的临床风险因素为吸烟(n=27)、年龄(n=25)、糖尿病史(n=22)、慢性胰腺炎(n=18)和体重指数(n=14)。
- 在25项评估模型性能的研究中,C统计量范围为0.61至0.98。
- 33项纳入研究中,基于PROBAST有6项被评为低偏倚风险。
关键数值与推荐
- PROBAST评估显示33项研究中6项为低偏倚风险。
- 25项评估模型性能的研究中C统计量为0.61至0.98。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出低偏倚风险研究仍需外部验证和实施研究,以确保这些模型将有益于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Identifying high-risk individuals using a risk prediction model could be a crucial first stage of screening pathways to improve the early detection of pancreatic cancer. A systematic review was conducted to critically evaluate the published primary literature on the development or validation of clinical risk prediction models for pancreatic cancer risk. METHODS: MEDLINE, Embase, and Web of Science were searched for relevant articles from the inception of each database up to November 2021. Study selection and data extraction were conducted by 2 independent reviewers. The Prediction model Risk Of Bias Assessment Tool (PROBAST) was applied to assess risk of bias. RESULTS: In total, 33 studies were included, describing 38 risk prediction models. Excluding studies with an overlapping population, this study consist of 15,848,100 participants, of which 58,313 were diagnosed with pancreatic cancer. Eight studies externally validated their model, and 13 performed internal validation. The studies described risk prediction models for pancreatic cancer in the general population (n = 14), patients with diabetes (n = 8), and individuals with gastrointestinal (and other) symptoms (symptoms included abdominal pain, unexplained weight loss, jaundice, and change in bowel habits and indigestion; n = 11). The commonly used clinical risk factors in the model were cigarette smoking (n = 27), age (n = 25), diabetes history (n = 22), chronic pancreatitis (n = 18), and body mass index (n = 14). In the 25 studies that assessed model performance, C-statistics ranged from 0.61 to 0.98. Of the 33 studies included, 6 were rated as being at a low risk of bias based on PROBAST. DISCUSSION: Many clinical risk prediction models for pancreatic cancer had been developed for different target populations. Although low risk-of-bias studies were identified, these require external validation and implementation studies to ensure that these will benefit clinical decision making.
引用
- Santos R, Coleman HG, Cairnduff V, et al. Clinical Prediction Models for Pancreatic Cancer in General and At-Risk Populations: A Systematic Review. Am J Gastroenterol. 2022. PMID: 36148840. doi:10.14309/ajg.0000000000002022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。